



# zymeworks

## Zymeworks to Present at Bloom Burton Healthcare Conference

April 13, 2021

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming 2021 Bloom Burton Healthcare Investor Conferencetaking place April 20-21, 2021.

The Company's presentation will be on Tuesday, April 20, 2021 at 11:30 a.m. ET.

Interested parties can access a live webcast of the presentation via a link from Zymeworks' website at <http://ir.zymeworks.com/events-and-presentations>, which will also host a recorded replay available afterwards.

### About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For additional information about Zymeworks, visit [www.zymeworks.com](http://www.zymeworks.com) and follow [@ZymeworksInc](https://twitter.com/ZymeworksInc) on Twitter.



View source version on [businesswire.com](https://www.businesswire.com/news/home/20210413005077/en/): <https://www.businesswire.com/news/home/20210413005077/en/>

Investor Inquiries:  
Ryan Dercho, Ph.D.  
(604) 678-1388  
[ir@zymeworks.com](mailto:ir@zymeworks.com)

Tiffany Tolmie  
(604) 678-1388  
[ir@zymeworks.com](mailto:ir@zymeworks.com)

Media Inquiries:  
Mary Klem  
(604) 678-1388  
[media@zymeworks.com](mailto:media@zymeworks.com)

Source: Zymeworks Inc.